• 尊龙凯时人生就博官网登录,ag尊龙凯时，尊龙凯时

    |
    EN
    |
    EN
    EN

    • 业务咨询

      中国：

      Email: marketing@clwgov.com

      业务咨询专线：400-780-8018

      （仅限服务咨询，其他事宜请拨打川沙总部电话）

      川沙总部电话: +86 (21) 5859-1500

      海外：

      +1(626)986-9880(U.S. - West Coast)

      0044 7790 816 954 (Europe)

      Email:marketing@medicilon.com
    在线留言×
    点击切换
    Customer Center
    客户中心

    研究人员设计合成STAT3和HDAC双通路抑制剂用于治疗实体肿瘤，PK实验通过尊龙凯时人生就博官网登录,ag尊龙凯时，尊龙凯时进行

    2023-07-05
    |
    访问量：

    56.png

    The inhibition of HDACs will lead to compensated activation of a notorious cancer-related drug target, STAT3, in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDAC inhibitors in solid tumors. 

    Herein, researchers synthesized a series of potent pterostilbene hydroxamic acid derivatives with dual-target inhibition activity. 

    The pharmacokinetic experiment in SD Rats was carried out by Medicilon.

    Reference:

    Yuhao Ren, et al. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer. J Med Chem. 2021 Jun 10;64(11):7468-7482. doi: 10.1021/acs.jmedchem.1c00136. 

    相关新闻
    友情链接: